[{"id":"eedda5a0-ec8c-4127-bb15-acd6b4c60d96","acronym":"SEQ-HN","url":"https://clinicaltrials.gov/study/NCT03719690","created_at":"2021-01-18T18:13:51.350Z","updated_at":"2024-07-02T16:36:00.691Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy","source_id_and_acronym":"NCT03719690 - SEQ-HN","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" HRAS","pipe":" | ","alterations":" RAS wild-type • HRAS mutation • HRAS wild-type","tags":["HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • HRAS mutation • HRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 284","initiation":"Initiation: 11/05/2018","start_date":" 11/05/2018","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-11-09"}]